{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=15", "query": { "condition": "Immune Dysfunction", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 20596, "total_pages": 2060, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T05:10:01.375Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02925117", "title": "A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 167, "start_date": "2016-10-25", "completion_date": "2019-01-31", "has_results": true, "last_update_posted_date": "2020-07-16", "last_synced_at": "2026-10-18T05:10:01.375Z", "location_count": 10, "location_summary": "Tampa, Florida • Sandy Springs, Georgia • Rockville, Maryland + 7 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "East Windsor", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02925117" }, { "nct_id": "NCT00006368", "title": "Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Breast Cancer", "Gastrointestinal Carcinoid Tumor", "Islet Cell Tumor", "Lung Cancer", "Lymphoma", "Melanoma (Skin)", "Neoplastic Syndrome" ], "interventions": [ { "name": "yttrium Y 90-edotreotide", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "1998-01", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2013-05-01", "last_synced_at": "2026-10-18T05:10:01.375Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006368" }, { "nct_id": "NCT00002013", "title": "A Safety, Pilot Pharmacokinetics and Neurocognitive Study of AS-101 in Combination With Zidovudine in AIDS/ARC Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Zidovudine", "type": "DRUG" }, { "name": "AS-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-18T05:10:01.375Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002013" }, { "nct_id": "NCT07624513", "title": "D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "Bortezomib (B)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Linvoseltamab", "type": "DRUG" }, { "name": "On Body Delivery System (OBDS)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 720, "start_date": "2026-08-31", "completion_date": "2038-03-01", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-18T05:10:01.375Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07624513" }, { "nct_id": "NCT00551720", "title": "Motivation and Patch Treatment for HIV-positive Smokers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections", "Smoking Cessation" ], "interventions": [ { "name": "Standard Care", "type": "BEHAVIORAL" }, { "name": "Motivational Enhancement", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "National Institute on Drug Abuse (NIDA)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 444, "start_date": "1999-01", "completion_date": "2004-12", "has_results": false, "last_update_posted_date": "2017-01-12", "last_synced_at": "2026-10-18T05:10:01.375Z", "location_count": 5, "location_summary": "Fall River, Massachusetts • New Bedford, Massachusetts • Pawtucket, Rhode Island + 1 more", "locations": [ { "city": "Fall River", "state": "Massachusetts" }, { "city": "New Bedford", "state": "Massachusetts" }, { "city": "Pawtucket", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00551720" }, { "nct_id": "NCT01535924", "title": "Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Lymphocyte Depletion Hodgkin Lymphoma", "Adult Lymphocyte Predominant Hodgkin Lymphoma", "Adult Mixed Cellularity Hodgkin Lymphoma", "Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma", "Adult Nodular Sclerosis Hodgkin Lymphoma", "Recurrent Adult Hodgkin Lymphoma" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "bendamustine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Christian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2012-02-09", "completion_date": "2019-02-20", "has_results": true, "last_update_posted_date": "2021-11-19", "last_synced_at": "2026-10-18T05:10:01.375Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Columbus, Ohio", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01535924" }, { "nct_id": "NCT00106379", "title": "Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Truvada (tenofovir DF + emtricitabine)", "type": "DRUG" }, { "name": "Emtriva (emtricitabine)", "type": "DRUG" }, { "name": "Viread (tenofovir DF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 52, "start_date": "2004-10", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2010-02-02", "last_synced_at": "2026-10-18T05:10:01.375Z", "location_count": 4, "location_summary": "Fort Lauderdale, Florida • Vero Beach, Florida • Baltimore, Maryland + 1 more", "locations": [ { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Vero Beach", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Harlingen", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00106379" }, { "nct_id": "NCT07699380", "title": "METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes (T1D)", "Metabolic Diseases", "Glucose Metabolism Disorders", "Endocrine System Diseases", "Autoimmune Diseases", "Immune System Diseases", "Diabetes Melletus, Type 1", "Nutritional and Metabolic Diseases", "Combination Therapy" ], "interventions": [ { "name": "AMX0035", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 60, "start_date": "2026-09", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-18T05:10:01.375Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07699380" }, { "nct_id": "NCT02239562", "title": "sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autoimmune Hepatitis" ], "interventions": [ { "name": "sPIF", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Christopher O'Brien, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 36, "start_date": "2014-11-14", "completion_date": "2016-12-29", "has_results": true, "last_update_posted_date": "2019-11-20", "last_synced_at": "2026-10-18T05:10:01.375Z", "location_count": 2, "location_summary": "Miami, Florida • Cherry Hill, New Jersey", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Cherry Hill", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02239562" }, { "nct_id": "NCT02226146", "title": "Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pemphigoid, Bullous" ], "interventions": [ { "name": "Bertilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 11, "start_date": "2016-02-29", "completion_date": "2018-04-30", "has_results": true, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-10-18T05:10:01.375Z", "location_count": 6, "location_summary": "Iowa City, Iowa • Buffalo, New York • New York, New York + 3 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02226146" } ] }